Covering Remdesivir – Contact an expert from Cedarville first

Covering Remdesivir – Contact an expert from Cedarville first Covering Remdesivir – Contact an expert from Cedarville first

May 4, 20202 min read
Featuring:


There has been a lot of talk about treatment, vaccinations and drugs that are being used during the CVOID-19 pandemic.


The latest is Remdesivir – and it is getting a lot of attention.


The US's Food and Drug Administration (FDA) has authorised emergency use of the Ebola drug remdesivir for treating the coronavirus.


The authorisation means the anti-viral drug can now be used on people who are hospitalised with severe Covid-19.


A recent clinical trial showed the drug helped shorten the recovery time for people who were seriously ill.


However, it did not significantly improve survival rates.


Experts have warned the drug - which was originally developed to treat Ebola, and is produced by Gilead pharmaceutical company in California - should not be seen as a "magic bullet" for coronavirus.




What do we know about remdesivir?


The drug did not cure Ebola, and Gilead says on its website: "Remdesivir is an experimental medicine that does not have established safety or efficacy for the treatment of any condition." Gilead also warns of possible serious side-effects.

However, President Trump has been a vocal supporter of remdesivir as a potential treatment for the coronavirus.


In its clinical trial, whose full results are yet to be released, the US National Institute of Allergy and Infectious Diseases (NIAID) found that remdesivir cut the duration of symptoms from 15 days down to 11.


The trials involved 1,063 people at hospitals around the world - including the US, France, Italy, the UK, China and South Korea. Some patients were given the drug and others were given a placebo (dummy) treatment.


Dr Anthony Fauci who runs NIAID, said that remdesivir had "a clear-cut, significant, positive effect in diminishing the time to recovery".


However, although remdesivir may aid recovery - and possibly stop people having to be treated in intensive care - the trials did not give any clear indication whether it can prevent deaths from coronavirus.  May 02 - BBC



There are still a lot of questions to be asked:


  • When could it be ready for mass distribution?
  • How is it administered?
  • Who can get it?
  • And how much will it cost?


If you are a journalist covering this emerging issue – then let our experts help.


Dr. Zach Jenkins is an infectious disease expert at Cedarville University. He is available to speak with media about this topic – simply click on his icon to arrange an interview.




Connect with:
  • Zachary Jenkins
    Zachary Jenkins Associate Professor of Pharmacy Practice

    Dr. Zach Jenkins is an infectious disease expert

powered by Powered By

You might also like...